Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)

Trial Profile

Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Acronyms REVRI
  • Most Recent Events

    • 23 Aug 2017 Planned End Date changed from 1 May 2021 to 1 Jan 2019.
    • 23 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top